Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

543
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
543
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling early human heart development using an iPSC-based 3D bioprinted model of embryonic heart tube.

Nature communications·2026
Same author

The impact of acute coronary syndrome on long-term survival in cancer patients.

Cardio-oncology (London, England)·2026
Same author

Non-coding RNAs in lipid metabolism and their roles in atherosclerosis.

Nature reviews. Cardiology·2026
Same author

Transient cardiomyopathy by tyrosine kinase inhibitor therapy: time to define a new syndrome in cardio-oncology?

European heart journal·2025
Same author

IGFBP2 Mediates Human iPSC-Cardiomyocyte Proliferation in a Cellular Contact-Dependent Manner.

Circulation research·2025
Same author

Decoding ETV2 networks driving endothelial specification and cardiac repression.

Cardiovascular research·2025

Related Experiment Video

Updated: Jun 13, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K

Insights Into Heart-Tumor Interactions in Heart Failure.

Tal Caller1,2, Kathryn J Moore3, Lorenz H Lehmann4,5,6

  • 1Neufeld and Tamman Cardiovascular Research Institutes, Faculty of Medical and Health Sciences, Tel Aviv University, Israel (T.C., J.L.).

Circulation Research
|May 22, 2025
PubMed
Summary
This summary is machine-generated.

Heart failure (HF) may promote cancer growth by releasing factors that fuel tumors. This review explores the complex link between HF and cancer, highlighting inflammation and immune system changes.

Keywords:
biomarkersheart failureimmune systeminflammationneoplasmsrisk factors

More Related Videos

The Inverted Heart Model for Interstitial Transudate Collection from the Isolated Rat Heart
07:59

The Inverted Heart Model for Interstitial Transudate Collection from the Isolated Rat Heart

Published on: June 20, 2017

8.3K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.6K

Related Experiment Videos

Last Updated: Jun 13, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K
The Inverted Heart Model for Interstitial Transudate Collection from the Isolated Rat Heart
07:59

The Inverted Heart Model for Interstitial Transudate Collection from the Isolated Rat Heart

Published on: June 20, 2017

8.3K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.6K

Area of Science:

  • Cardiology
  • Oncology
  • Immunology

Background:

  • Heart failure (HF) and cancer frequently coexist.
  • HF is linked to increased cancer incidence, sharing risk factors and mechanisms.
  • The bidirectional relationship between HF and cancer is complex and not fully understood.

Purpose of the Study:

  • To review the biological crosstalk between HF and cancer.
  • To emphasize HF's impact on tumor growth via inflammation and immune modulation.
  • To explore clinical implications and propose future research.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of shared risk factors and biological mechanisms.
  • Discussion of inflammatory and immunological pathways.

Main Results:

  • Preclinical evidence suggests HF can promote tumor growth.
  • Inflammation and immune system modulation are key mechanisms in HF-cancer crosstalk.
  • Shared factors worsen outcomes for patients with both conditions.

Conclusions:

  • HF may act as a protumorigenic condition.
  • Understanding HF-cancer interactions can lead to new biomarkers and therapies.
  • Integrated approaches to diagnosis, prevention, and treatment are needed.